Plain-English answer
Evidence strategy for China market access must answer different questions for different institutions. NMPA asks whether the product is safe, effective, and quality-controlled for approval. NHSA asks whether public insurance should pay and at what price. Hospitals ask whether the product fits clinical workflow, procurement rules, and budget constraints. Physicians ask whether it helps a real patient pathway. One evidence package rarely satisfies all four audiences.
Market context
China's regulatory system increasingly accepts structured global evidence when it meets Chinese requirements, but the reimbursement system is becoming more value- and budget-sensitive. NRDL negotiation, centralized procurement, DRG/DIP payment reform, and medical-insurance fund supervision all create demand for economic evidence, not only clinical efficacy. For devices, hospital adoption may depend on procedure time, complication reduction, consumable cost, training burden, and service support.
Evidence is also local. Chinese epidemiology, diagnostic rates, treatment patterns, hospital level, patient affordability, and comparator availability may differ from U.S. or European assumptions. A U.S. pivotal trial can establish credibility but still leave China-specific questions about eligible population, hospital workflow, and budget impact.
Operating model
A China evidence plan should separate regulatory evidence, payer evidence, hospital evidence, and medical-affairs evidence. Regulatory evidence focuses on safety, effectiveness, quality, and appropriate claims. Payer evidence focuses on clinical value, unmet need, budget impact, alternative therapy cost, and population size. Hospital evidence focuses on workflow, length of stay, readmission, staff burden, consumable use, complication avoidance, and revenue or payment implications.
Real-world evidence may be useful after launch, but only if data permissions, data quality, endpoints, and hospital participation are planned early. For genomics, rare disease, oncology, and AI, human genetic resources and personal information rules may affect study design and data transfer.
Strategic reading
Good evidence strategy starts before China registration. The company should decide whether Chinese sites should participate in global trials, whether bridging data are needed, whether the comparator is the Chinese standard of care, and whether the endpoints matter to Chinese hospitals and payers. A product that saves cost in a U.S. DRG environment may not save cost under a Chinese hospital's payment rules.
The goal is not simply more evidence. It is decision-specific evidence. A targeted therapy may need biomarker prevalence and testing access; a device may need procedure economics; a digital tool may need workflow and data-security validation; a hospital service may need patient-flow and quality metrics.
Implementation detail
Evidence planning should also include negative evidence: what would make the product unattractive in China? A device may improve a technical endpoint but increase length of stay. A drug may improve survival but require testing that is unavailable outside top hospitals. A digital tool may reduce physician time in theory but require data entry that nurses cannot absorb.
By defining failure modes early, the company can design studies that answer real adoption questions. The evidence plan should include endpoints for regulators, payers, hospital administrators, clinicians, and patients, with a clear explanation of which endpoint supports which decision.